Canada markets closed

Windtree Therapeutics, Inc. (WINT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1683+0.0024 (+1.45%)
At close: 04:00PM EST
0.1700 +0.00 (+1.01%)
After hours: 07:50PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.1659
Open0.1698
Bid0.1674 x 2200
Ask0.1700 x 800
Day's Range0.1610 - 0.1720
52 Week Range0.1400 - 1.4300
Volume882,941
Avg. Volume513,750
Market Cap6.498M
Beta (5Y Monthly)0.20
PE Ratio (TTM)N/A
EPS (TTM)-2.4370
Earnings DateMar 29, 2023 - Apr 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • GlobeNewswire

    Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants

    WARRINGTON, Pa., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”) today announced it has entered into warrant inducement offer letters (the “Inducement Offer Letters”) to raise approximately $1.0 million in gross proceeds from the exercise of warrants to purchase 4,808,595 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), in the aggregate. Pursuant to the Inducement Offer Letters, the Company agreed to red

  • GlobeNewswire

    Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance

    WARRINGTON, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the NASDAQ Stock Market (“Nasdaq”) has granted Windtree an additional 180 days to regain compliance with Nasdaq’s $1.00 minimum bid price rule requirement under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”), following the expiration of

  • Zacks

    Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why

    Windtree Therapeutics, Inc. (WINT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).